Company: PMVP
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0000950170-25-030414
Chunk: 162

Company: PMV Pharmaceuticals, Inc.
Filing Date: 2025-03-03
Form: 10-K
Item: Item 1B
Chunk 162
---
. To date, there have not been any material adjustments to our prior estimates of accrued research and development expenses.

 99

Recent Accounting Pronouncements

For a description of recent accounting pronouncements, see Note 2 of the notes to our audited consolidated financial statements for the year ended December 31, 2024 included elsewhere in this Annual Report on Form 10-K.

Item 7A.  Reserved. 

 100

Item 8. Consolidated Financial Statements and Supplementary Data. 

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

Audited Consolidated Financial Statements 

    Report of Ernst & Young LLP, Independent Registered Public Accounting Firm (PCAOB ID: 42)
    102

    Consolidated Balance Sheets as of December 31, 2024 and 2023
    104

    Consolidated Statements of Operations and Comprehensive Loss for the Years Ended December 31, 2024, 2023, and 2022 
    105

    Consolidated Statements of Stockholders’ Equity (Deficit) for the Years Ended December 31, 2024, 2023, and 2022
    106

    Consolidated Statements of Cash Flows for the Years Ended December 31, 2024, 2023, and 2022
    107

    Notes to Consolidated Financial Statements
    108

 101

Report of Independent Registered Public Accounting Firm

To the Stockholders and the Board of Directors of PMV Pharmaceuticals, Inc.

Opinion on the Financial StatementsWe have audited the accompanying consolidated balance sheets of PMV Pharmaceuticals, Inc. (the Company) as of December 31, 2024 and 2023, the related consolidated statements of operations and comprehensive loss, stockholders’ equity (deficit) and cash flows for each of the three years in the period ended December 31, 2024, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2024, in conformity with U.S. generally accepted accounting principles.

Basis for Opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial